Literature DB >> 10517946

Imaging of brain tumors after therapy.

S J Nelson1.   

Abstract

Imaging is used routinely for the diagnosis and follow-up of patients with brain tumors. Although the latest MR imaging techniques are able to provide an excellent depiction of abnormalities in soft tissue morphology, they are frequently unable to distinguish edema and treatment-induced necrosis from recurrent or residual tumor. For assessment of response to therapy, it is therefore important to use functional imaging modalities such as PET and MR spectroscopy.

Entities:  

Mesh:

Year:  1999        PMID: 10517946

Source DB:  PubMed          Journal:  Neuroimaging Clin N Am        ISSN: 1052-5149            Impact factor:   2.264


  9 in total

1.  [Preoperative imaging as the basis for image-guided neurosurgery].

Authors:  D Winkler; G Strauss; S Hesse; A Goldammer; M Hund-Georgiadis; A Richter; O Sabri; T Kahn; J Meixensberger
Journal:  Radiologe       Date:  2004-07       Impact factor: 0.635

2.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

3.  Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging.

Authors:  Esin Ozturk-Isik; Andrea Pirzkall; Kathleen R Lamborn; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

4.  Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids.

Authors:  Edward F Jackson; Emilio Esparza-Coss; Xiaoxia Wen; Chaan S Ng; Sherita L Daniel; Roger E Price; Belinda Rivera; Chusilp Charnsangavej; Juri G Gelovani; Chun Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-26       Impact factor: 7.038

5.  123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study.

Authors:  Michail Plotkin; Julia Eisenacher; Harald Bruhn; Reinhard Wurm; Roger Michel; Florian Stockhammer; Annelie Feussner; Oliver Dudeck; Peter Wust; Roland Felix; Holger Amthauer
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

6.  Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo.

Authors:  Arunav Kumar; Sreedharan Thankarajan ArunRaj; Khush Bhullar; K P Haresh; Subhash Gupta; Sanjana Ballal; Madhav Yadav; Manmohan Singh; Nishikant Avinash Damle; Ajay Garg; Madhavi Tripathi; Chandrasekhar Bal
Journal:  Neuroradiology       Date:  2021-10-14       Impact factor: 2.804

7.  Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.

Authors:  Gabriele Pöpperl; Claudia Götz; Walter Rachinger; Franz-Josef Gildehaus; Jörg-Christian Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-10       Impact factor: 9.236

8.  Diagnostics of cerebral gliomas with radiolabeled amino acids.

Authors:  Karl-Josef Langen; Klaus Tatsch; Anca-Ligia Grosu; Andreas H Jacobs; Matthias Weckesser; Osama Sabri
Journal:  Dtsch Arztebl Int       Date:  2008-01-25       Impact factor: 5.594

Review 9.  Use of 99m-technetium-glucoheptonate as a tracer for brain tumor imaging: An overview of its strengths and pitfalls.

Authors:  Amburanjan Santra; Rakesh Kumar; Punit Sharma
Journal:  Indian J Nucl Med       Date:  2015 Jan-Mar
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.